论文部分内容阅读
目的探讨CT引导下经皮穿刺植入放射性粒子125I联合DP方案治疗非小细胞肺癌(NSCLC)的临床疗效及不良反应。方法 56例ⅡB-ⅢB期NSCLC患者分为治疗组(放射性粒子125I植入+化疗)27例和对照组(放射性粒子125I植入)29例,观察有效率、疾病稳定率及毒副反应。有效率、疾病稳定率采用χ2检验。结果治疗组有效率分别为:63.0%,70.4%,77.8%,66.7%;疾病控制率分别为:85.2%,81.5%,92.6%,88.9%;对照组有效率分别为:37.9%,41.4%,48.3%,51.7%;疾病控制率分别为:58.6%,55.2%,69.0%,62.1%;化疗2周期有效率两组差异无统计学意义,化疗2周期疾病控制率差异有统计学意义,化疗4周期,化疗后3月、6月有效率及疾病控制率差异均有统计学意义。结论放射性粒子125I联合DP方案治疗局部晚期非小细胞肺癌(NSCLC)疗效显著,患者耐受良好,是一种安全、有效的治疗方法。
Objective To investigate the clinical efficacy and adverse reactions of CT guided percutaneous implantation of 125I combined with DP regimen in the treatment of non-small cell lung cancer (NSCLC). Methods Fifty-six patients with stage ⅡB-ⅢB NSCLC were divided into treatment group (radioactive 125I implantation + chemotherapy) and control group (radioactive 125I implantation). The effective rate, disease stability rate and toxicity were observed. Efficacy, disease stability rate using χ2 test. Results The effective rates in the treatment group were 63.0%, 70.4%, 77.8% and 66.7% respectively. The disease control rates were 85.2%, 81.5%, 92.6% and 88.9% respectively. The effective rates in the control group were 37.9% and 41.4% , 48.3% and 51.7% respectively. The disease control rates were 58.6%, 55.2%, 69.0% and 62.1% respectively. There was no significant difference in the two cycles of chemotherapy between the two groups, The 4 cycles of chemotherapy, 3 months after chemotherapy, 6 months effective rate and disease control rate differences were statistically significant. Conclusion The combination of radioactive 125I with DP regimen in the treatment of locally advanced non-small cell lung cancer (NSCLC) has a significant effect and is well tolerated. It is a safe and effective treatment.